Sanofi $SNY Shares Bought by Ritholtz Wealth Management

Ritholtz Wealth Management lifted its position in shares of Sanofi (NASDAQ:SNY) by 48.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 45,685 shares of the company’s stock after buying an additional 14,880 shares during the quarter. Ritholtz Wealth Management’s holdings in Sanofi were worth $1,884,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the company. Root Financial Partners LLC acquired a new position in Sanofi in the third quarter valued at $27,000. Western Wealth Management LLC acquired a new stake in Sanofi during the 1st quarter worth about $29,000. Signature Equity Partners LLC grew its holdings in Sanofi by 322.2% during the 3rd quarter. Signature Equity Partners LLC now owns 857 shares of the company’s stock worth $35,000 after acquiring an additional 654 shares during the period. Financial Network Wealth Advisors LLC raised its position in shares of Sanofi by 103.3% in the 3rd quarter. Financial Network Wealth Advisors LLC now owns 911 shares of the company’s stock worth $38,000 after acquiring an additional 463 shares in the last quarter. Finally, Provenance Wealth Advisors LLC raised its position in shares of Sanofi by 359.8% in the 3rd quarter. Provenance Wealth Advisors LLC now owns 2,322 shares of the company’s stock worth $96,000 after acquiring an additional 1,817 shares in the last quarter. Institutional investors own 14.03% of the company’s stock.

Sanofi Stock Down 0.2%

NASDAQ:SNY traded down $0.09 during trading hours on Friday, reaching $48.37. The company had a trading volume of 1,675,700 shares, compared to its average volume of 4,657,690. The company has a quick ratio of 0.27, a current ratio of 1.12 and a debt-to-equity ratio of 0.20. The firm has a market cap of $117.27 billion, a price-to-earnings ratio of 23.95, a P/E/G ratio of 1.33 and a beta of 0.31. The business’s 50-day simple moving average is $42.68 and its two-hundred day simple moving average is $44.38. Sanofi has a twelve month low of $39.07 and a twelve month high of $52.67.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Friday, October 30th. The company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.56 by $0.48. The firm had revenue of $17.25 billion for the quarter, compared to analyst estimates of $14.30 billion. Sanofi had a net margin of 8.70% and a return on equity of 15.16%. The business’s quarterly revenue was up 16.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.91 earnings per share. On average, equities analysts expect that Sanofi will post 5.07 earnings per share for the current year.

Wall Street Analysts Forecast Growth

SNY has been the topic of a number of recent analyst reports. DZ Bank reissued a “buy” rating on shares of Sanofi in a research note on Friday, July 31st. BNP Paribas Exane raised Sanofi from a “neutral” rating to an “outperform” rating and set a $57.00 target price for the company in a research note on Monday, November 9th. Sanford C. Bernstein reiterated a “buy” rating on shares of Sanofi in a report on Monday, August 3rd. Wall Street Zen upgraded Sanofi from a “hold” rating to a “buy” rating in a report on Saturday, November 7th. Finally, HSBC reissued a “buy” rating on shares of Sanofi in a research note on Thursday, September 10th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and twelve have assigned a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $53.00.

Sanofi Company Profile

Sanofi is a France-based global biopharmaceutical company that researches, develops, manufactures and markets medicines and vaccines. Its work spans areas including immunology, oncology, rare diseases and neurology, as well as preventive vaccines. The company’s portfolio includes Dupixent, an immunology medicine developed with Regeneron, and vaccines for diseases such as influenza and meningitis. Sanofi serves patients and healthcare providers in markets around the world. Sanofi traces its origins to a company established in France in 1973.